Re-irradiation stereotactic body radiotherapy for spinal metastases: a multi-institutional outcome analysis

Ahmed Hashmi, MD,1 Matthias Guckenberger, MD,2,3 Ron Kersh, MD,4 Peter C. Gerszten, MD,5 Frederick Mantel, MD,2 Inga S. Grills, MD,6 John C. Flickinger, MD,7 John H. Shin, MD,8 Daniel K. Fahim, MD,9 Brian Winey, PhD,10 Kevin Oh, MD,10 B. C. John Cho, MD, PhD,11 Daniel Létourneau, PhD,11 Jason Sheehan, MD, PhD,12 and Arjun Sahgal, MD1

1Department of Radiation Oncology, Sunnybrook Odette Cancer Centre, and 2Department of Radiation Oncology, Princess Margaret Cancer Center, University of Toronto, Ontario, Canada; 3Department of Radiation Oncology, Riverside Medical Center, Newport News, Virginia; Departments of 4Neurosurgery and 5Radiation Oncology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; 6Department of Radiation Oncology, University of Wuerzburg, Germany; Departments of 7Radiation Oncology and 8Neurosurgery, William Beaumont Hospital, Royal Oak, Michigan; Departments of 9Neurosurgery and 10Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts; 11Department of Neurosurgery, University of Virginia Health System, Charlottesville, Virginia; and 12Department of Radiation Oncology, University of Zurich, Zurich, Switzerland

OBJECTIVE This study is a multi-institutional pooled analysis specific to imaging-based local control of spinal metastases in patients previously treated with conventional external beam radiation therapy (cEBRT) and then treated with re-irradiation stereotactic body radiotherapy (SBRT) to the spine as salvage therapy, the largest such study to date.

METHODS The authors reviewed cases involving 215 patients with 247 spinal target volumes treated at 7 institutions. Overall survival was calculated on a patient basis, while local control was calculated based on the spinal target volume treated, both using the Kaplan-Meier method. Local control was defined as imaging-based progression within the SBRT target volume. Equivalent dose in 2-Gy fractions (EQD2) was calculated for the cEBRT and SBRT course using an α/β of 10 for tumor and 2 for both spinal cord and cauda equina.

RESULTS The median total dose/number of fractions of the initial cEBRT was 30 Gy/10. The median SBRT total dose and number of fractions were 18 Gy and 1, respectively. Sixty percent of spinal target volumes were treated with single-fraction SBRT (median, 16.6 Gy and EQD2/10 = 36.8 Gy), and 40% with multiple-fraction SBRT (median 24 Gy in 3 fractions, EQD2/10 = 36 Gy). The median time interval from cEBRT to re-irradiation SBRT was 13.5 months, and the median duration of patient follow-up was 8.1 months. Kaplan-Meier estimates of 6- and 12-month overall survival rates were 64% and 48%, respectively; 13% of patients suffered a local failure, and the 6- and 12-month local control rates were 93% and 83%, respectively. Multivariate analysis identified Karnofsky Performance Status (KPS) < 70 as a significant prognostic factor for worse overall survival, and single-fraction SBRT as a significant predictive factor for better local control. There were no cases of radiation myelopathy, and the vertebral compression fracture rate was 4.5%.

CONCLUSIONS Re-irradiation spine SBRT is effective in yielding imaging-based local control with a clinically acceptable safety profile. A randomized trial would be required to determine the optimal fractionation.

http://thejns.org/doi/abs/10.3171/2016.4.SPINE151523

KEY WORDS spinal metastases; re-irradiation; stereotactic body radiotherapy; stereotactic radiosurgery; salvage; oncology

Spinal metastases will develop in 40% of patients diagnosed with cancer. Most of these patients will be offered short-course palliative conventional external beam radiation therapy (cEBRT), which has been associated with short-term pain control and low rates of complete response to pain.24 Furthermore, approximately 10%–20% of patients will suffer pain progression following cEBRT, requiring retreatment.18 Therefore, the burden of patients needing re-irradiation to spinal metastases is significant, considering the prevalence of the disease.

Retreatment options are limited and have typically consisted of a second course of cEBRT delivering a lower
dose than the first course or a biologically equivalent dose in order to respect cumulative risks of radiation-induced toxicities. This strategy has been investigated in a landmark randomized trial evaluating re-irradiation cEBRT doses of 20 Gy in 5 fractions and 8 Gy in 1 fraction for painful bone metastases requiring retreatment. The trial confirmed that response rates are suboptimal, with only 30% of patients achieving an overall pain response to treatment. These data highlight the need for more effective treatments in the retreatment indication. It is also important to recognize that the decision to re-irradiate with additional cEBRT limits further treatment options significantly due to toxicity concerns, and this is of particular relevance to spinal metastases because the spinal cord and cauda equina (critical neural tissue [CNT]) can tolerate only so much cumulative exposure.

Stereotactic body radiotherapy (SBRT) has been defined by several national and international bodies and associations as the precise delivery of highly conformal image-guided hypofractionated (> 5 Gy/fraction) EBRT, delivered in a single fraction or a few fractions, to an extracranial body target with doses at least biologically equivalent to those considered radical when given over a protracted course. Spine SBRT is an emerging treatment option and is designed to escalate the dose to the spinal metastasis while maintaining a lower dose exposure for critical neural tissues (CNTs, namely the spinal cord and the thecal sac as a surrogate for the cauda equina). In the retreatment indication, spine SBRT has major potential for effective palliation and local tumor control, because substantially higher radiation doses are delivered as compared with the first course of cEBRT. The few retreatment SBRT series that have been reported indicate high rates of treatment efficacy, but these series are limited with respect to sample size and are single-center studies by design. The present study consists of the largest multi-institutional pooled analysis reporting on imaging-based local control rates in patients previously treated with cEBRT and subsequently treated with re-irradiation SBRT with salvage intent.

**Methods**

**Patient Population and SBRT Technique**

Seven international centers from the United States, Canada, and Germany, took part in this research ethics board–approved retrospective study. A total of 215 patients were included. Each patient had spinal metastases treated with SBRT with salvage intent (failure of prior cEBRT). All centers were members of the Elekta Spine Study Consortium (ESSC). The principles and practice of each member of this consortium’s technique, approach to organs at risk, targeting, and dosimetric aims have been previously reported.

Patients were treated most frequently with an Elekta (Elekta AB) subcentimeter multileaf collimator (4 mm) linear accelerator–based SBRT apparatus equipped with cone-beam CT (CBCT)–based image-guidance, online correction of setup errors in 6 degrees of freedom using the robotic HexaPOD patient positioning platform (Elekta AB), and either intensity-modulated radiotherapy or volumetric modulated radiotherapy. Patients were immobilized using the BodyFIX system (Elekta AB) for tumors below T-4, and for tumors at T-4 and above (cranially) in a head and neck 5-point thermoplastic mask. This technology has been reported to yield, based on a strict repositioning threshold of 1 mm and 1°, target localization within 1.2 mm and 0.9° with 95% confidence. Treatment planning systems and technique were not standardized between the different institutes. Contouring of the target volume was typically based on the International Spine Radiosurgical Consortium (ISRC) guidelines. Technical and delivery details can be reviewed in prior reported studies that include a survey of ESSC institutional practices and delivery techniques.

Biologically equivalent dose (BED) in 2-Gy–equivalent fractions, known as the equivalent dose in 2-Gy fractions (EQD2), was calculated for the tumor based on the prescription dose and number of fractions and the CNT based on the point maximum dose (Dmax) to adjust for variation in dose-fractionation schemes among institutions. An α/β ratio of 10 was used for tumor calculation and an α/β ratio of 2 for the CNT. The spinal cord was typically contoured according to the spinal cord plus a 1.5–2.0 mm PRV, and the cauda equina contoured according to the thecal sac.

**Radiographic and Clinical Assessments After SBRT**

Local control was assessed radiologically with MRI, and in some centers confirmed with FDG-PET. Local failure was defined as tumor progression in the previously treated volume as determined by the radiation oncologist and radiologist in accordance with the recently reported Spine Response Assessment In Neuro-Oncology (SPINO) guideline. Pain status at baseline and follow-up was categorized as none, mild to moderate, or severe. No specific criteria were applied. We evaluated the SBRT spinal segment and characterized the target volume as single for isolated metastases and multiple if the target consisted of contiguous vertebrae. In situations where noncontiguous single spinal segments were treated, then each segment was considered as a single target rather than considering the lesions as a multiple-segment target volume.

**Statistical Methods**

Statistical analysis was performed on Statistica X (Statsoft), and all statistical tests were 2-sided. The Pearson chi-square or Fisher exact test and Kruskal-Wallis ANOVA were used to compare categorical and continuous variable between groups. Receiver operating characteristics curves were used to test prognostic factors in predicting outcome with their performances measured based on the area under the curve. The Kaplan-Meier method was used to estimate the likelihood of events from the date of SBRT to last follow-up. Log-rank test was used to compare differences in the univariate analysis. A Cox proportional hazard model was used to perform multivariate analysis.

**Results**

**Patient and Tumor Characteristics**

Table 1 summarizes selected baseline patient and treatment-related characteristics. A total of 215 patients and
247 spinal target volumes were followed with a median clinical follow-up time of 8.1 months, and the median imaging-based follow-up time was 7.7 months. SBRT was performed as salvage treatment after cEBRT failures, and no boost practice was included in this series. Eighty-nine percent of patients had multiple contiguous vertebrae as the target volume (median 2 segments); 85.2% had radiographic evidence of no epidural disease or low-grade epidural disease (indenting the thecal sac but not deforming the spinal cord), based on the Bilsky classification. Only 14.8% had features of high-grade epidural disease (Bilsky Grade 2 or 3 status). Paraspinal disease was present in 55.8% of patients, and 32.8% had preexisting vertebral compression fractures. Baseline mild to moderate pain prior to SBRT was reported in 78.1% of the patients. Forty-six percent had undergone surgical treatment prior to SBRT; the surgical procedures are summarized in Table 1.

### SBRT Parameters

The median SBRT total dose was 18 Gy (range 8–50 Gy), the median number of fractions was 1 (range 1–20), the median EQD2/10 was 36 Gy (range 12.0–66.7 Gy), and the median CNT Dmax EQD2/2 was 24.6 (range 0–70.1 Gy). The median cEBRT total dose and number of fractions were 30 Gy and 10. Including prior cEBRT, the me-
The median cumulative EQD2/10 for tumor was 68.2 Gy, and the cumulative CNT EQD2/2 $D_{\text{max}}$ was 60.8 Gy.

When segregating those patients treated with multiple-fraction SBRT (40%) versus single-fraction SBRT (60%), the EQD2/10 for tumor was 36.0 Gy and 36.8 Gy, respectively, and the EQD2/2 to CNT was 15.3 Gy and 30 Gy, respectively. The cumulative EQD2/10 for tumor was 66.9 Gy and 67.6 Gy, respectively, and the EQD2/2 to CNT was 47.8 Gy and 63.6 Gy, respectively. The overall median interval between previous cEBRT and re-irradiation SBRT was 13.5 months. For single-fraction versus multiple-fraction SBRT, the time intervals between prior cEBRT and re-irradiation SBRT were 12 months and 16 months, respectively.

Clinical and Radiological Outcomes

One hundred thirty-three deaths were observed. The median overall survival was 11.8 months (range 8.6–15.0 months) with actuarial rates of 64% and 48% at 6 and 12 months, respectively. The Kaplan-Meier plot is shown in Fig. 1, displaying that 13% of patients suffered a local failure. The actuarial rate was 93% and 83% at 6 and 12 months, respectively. The median time to local failure for the entire cohort was 8.3 months (range 0.7–50.9 months). The median time to local failure was 8.2 months (range 2.6–17 months) in the single-fraction SBRT cohort and 11.3 (range 0.7–50.9) months in the multiple-fraction cohort.

Two hundred fourteen of the 215 patients had sufficient documentation of baseline predictive factors for survival analysis, with KPS at baseline a mandatory a priori field. Therefore, we present the survival prognostic factor univariate and multivariate analysis for this cohort. Data from at least 3 months of follow-up and at least 3 follow-up images were available for assessment of local control for 235 of 247 target volumes. Therefore, the predictive factor analysis for local control is based on this cohort. Table 2 summarizes those patient and treatment baseline variables that achieved significance ($p < 0.05$) on univariate analysis for both local control and overall survival. Multivariate analysis identified a KPS < 70 to be the only significant prognostic variable for survival ($p = 0.02$, 95% CI = 0.41–0.95, Fig. 2). With respect to local control, single-fraction SBRT was identified as the only significant predictive factor with single-fraction SBRT yielding better local control than multiple-fraction SBRT ($p = 0.002$, 95% CI = 1.7–13.5, Fig. 2). With respect to pain control, 74.3% of patients reported clinical improvement in pain. At last follow-up, pain was present in only 46.1% of patients.

Adverse Effects Following SBRT

Following SBRT, 11.3% of patients experienced dysphagia, 3% had dermatitis, and 12.4% had increased pain (the pain flare was mild to moderate in 65.3% of these cases and severe in 34.7%). With respect to late effects, no patient developed radiation-induced myelopathy or radiculopathy. Eleven vertebral compression fractures (VCFs) were observed (rate of 4.5%); 5 were de novo and 6 were fracture progression (rates of 2.1% and 2.5%, respectively).

Discussion

This study reports a comprehensive multi-institutional analysis of a large cohort of patients treated with re-irradiation SBRT for metastatic disease in the spine. The study found a favorable 12-month local control rate of 83% and a 12-month overall survival rate of 48%. The patient population consisted predominantly of lung, breast, and kidney cancer patients with metastatic lesions in thoracic and/or lumbar spinal segments and no or low-grade epidural disease.

With respect to local control, the data from the study by Garg et al.12 (as one of the only prospective retreatment SBRT series reported) consisted of outcomes for 59 patients and 63 tumors. The retreatment SBRT doses were 30 Gy in 5 fractions or 27 Gy in 3 fractions, and the CNT dose limits were less than 9–10 Gy. The authors reported a local control rate of 76% at 1 year, which is similar to our reported rate of 83%. Table 3 is a summary of the pub-
lished literature specific to retreatment SBRT, and we observe that our rates of survival and local control are consistent with those reported by other authors. To date there are no randomized trials comparing re-irradiation cEBRT to SBRT to definitively confirm superior efficacy.

With respect to overall survival, on multivariate analysis, performance status at the time of retreatment SBRT was observed to be the only statistically significant prognostic factor. Figure 2 describes the survival results for those patients with a KPS < 70 versus ≥ 70, determined at the time of retreatment SBRT. At 1 year after SBRT, 1.4% of patients with a KPS < 70 were alive as opposed to 36.9% of patients with a KPS ≥ 70. Our observation of KPS as a prognostic factor is consistent with Damast et al.10 in their re-irradiation SBRT series, and from Chao et al.,5 who also report on the prognostic capacity of KPS but in patients with no prior radiation therapy treated with spine SBRT. Thus far the spine SBRT literature supports the American Society for Radiation Oncology recommendations that a poor KPS (KPS < 40–50) can be considered an exclusion criterion for spine SBRT.21 Our data support its application to the retreatment indication. Moreover, patients in this population usually have already undergone a substantial amount of treatment and are relatively far along the trajectory of their metastatic disease, and a KPS ≥ 70 may be an appropriate inclusion criteria. However, it is important to note that if a patient’s KPS is < 70 due to the spinal metastases to be treated, aggressive treatment of the spinal metastases may lead to improvement of the KPS. Therefore, in determining whether re-irradiation SBRT is appropriate in any given case, it is essential to consider the individual patient and his or her specific needs.

With respect to local control, from the literature review summarized in Table 3, the presence of epidural disease, lack of space between the CNT and target, paraspinal disease extension, dose, and a shorter time interval between cEBRT and SBRT have been predictors. Our multivariate analysis identified retreatment SBRT with a single fraction to be a positive predictive factor, as compared with multiple-fraction SBRT. Figure 2 illustrates the local control rates for single- versus multiple-fraction SBRT. At 1 year, local control in those treated with single-fraction SBRT was 90%, compared with 73% in those treated with multiple-fraction SBRT.

Why was this fractionation result observed? With respect to the tumor, for single-fraction and multiple-fraction SBRT, both the SBRT EQD2/10 and cumulative EQD2/10 were similar (36.0 Gy and 66.9 Gy, and 36.8 Gy and 67.6 Gy, respectively). However, the CNT EQD2/2 Dmax and cumulative CNT EQD2/2 Dmax were greater for single-fraction SBRT than for multiple-fraction SBRT (30 Gy and 65.6 Gy, and 15.3 Gy and 47.8 Gy, respectively). When applied to univariate analysis, these factors failed to reach significance, and this may be a function of the small number of events in a small patient cohort. However, based on the physical CNT EQD2/2 SBRT Dmax being approximately 50% lower in the multiple-fraction cohort, we surmise that this (the CNT EQD22 SBRT Dmax) may still explain the result—the implication being that the epidural space and effectively the posterior aspect of the vertebral body bone were relatively underdosed in this cohort. We
are in the process of centrally reviewing all imaging and dosimetry for a pattern of failure analysis. Of note, our cohort consisted predominantly of patients with no epidural disease or low Bilsky grade disease (75.2% of the cohort), and the proportion of low-grade vs high-grade epidural disease was not identified on univariate analysis as predictive. On further analysis we confirmed that the proportion of cases of high-grade epidural disease (Grade 2 or 3) was similar in patients treated with single- or multiple-fraction SBRT (32% vs 44%, respectively) and, therefore, likely does not explain the result that single-fraction SBRT yielded better local control than multiple-fraction SBRT.

Could single-fraction SBRT be biologically favorable as compared with multiple-fraction SBRT? At present, there are uncontrolled data supporting single-fraction SBRT versus multiple-fraction SBRT and vice versa. Similarly, radiobiological rationales have been discussed supporting either approach. Those that support single-fraction high-dose SBRT argue that enhanced tumor vascular effects and endothelial cell apoptosis yield greater local tumor control, and these pathways are not otherwise activated with more fractionated low dose per fraction regimens. Additionally, high-dose single-fraction SBRT may induce an additional mechanism of tumor cell death via tumor reperfusion injury. The limited data suggest that a dose per fraction of at least 8–10 Gy, or even up to 15 Gy, is required for these unique effects. In our series, the median dose per fraction was 16.6 Gy in the single-fraction SBRT cohort and 8 Gy in the multiple-fraction cohort. Moreover, in the multiple-fraction cohort, 47% of the patients were treated with < 8 Gy per fraction regimens. It may be that using low-dose hypofractionated SBRT could have contributed to our higher rates of local failure as has been suggested by other studies. Of note, when comparing the outcomes using the EDQ2, the linear quadratic formula may overestimate the radiobiological effects with high dose per fraction regimens (> 15 Gy), and the ability to use the EQD2 as a tool to generate equivalent doses for

### TABLE 3. Summary of the current literature specific to re-irradiation SBRT

<table>
<thead>
<tr>
<th>Authors &amp; Year</th>
<th>No. of Tumors/Pts Treated</th>
<th>Median Follow-Up (mos)</th>
<th>Local Control</th>
<th>Complete Pain Response</th>
<th>OS</th>
<th>Median Tumor Dose/No. of Fractions (previous cEBRT)</th>
<th>Significant Predictors of Local Control</th>
<th>Significant Prognostic Factors for OS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sahgal et al., 2009</td>
<td>37/25</td>
<td>7</td>
<td>96% @ 1 yr</td>
<td>NA</td>
<td>45% @ 2 yrs</td>
<td>24 Gy/3 Fx (median dose 36 Gy/14 Fx)</td>
<td>Distance btw GTV &amp; CNS &lt;1 mm</td>
<td>NA</td>
</tr>
<tr>
<td>Choi et al., 2010</td>
<td>51/42</td>
<td>7</td>
<td>87% @ 6 mos/73% @ 1 yr</td>
<td>65%</td>
<td>68% @ 1 yr</td>
<td>Median 20 Gy/2 Fx (median cEBRT EQD2 = 40 Gy)</td>
<td>&lt;12-mo time interval btw cEBRT &amp; SBRT; presence of epidural disease</td>
<td>NA</td>
</tr>
<tr>
<td>Mahadevan et al., 2011</td>
<td>81/60</td>
<td>12</td>
<td>93% @ last follow-up</td>
<td>NA</td>
<td>Median OS: 11 mos</td>
<td>25–30 Gy/5 Fx or 24 Gy/3 Fx (median dose 30 Gy/10 Fx)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Garg et al., 2011</td>
<td>63/59</td>
<td>17.6</td>
<td>76% @ 1 yr</td>
<td>NA</td>
<td>76% @ 1 yrs</td>
<td>27 Gy/3 Fx or 30 Gy/5 Fx (median dose 30 Gy/NA Fx)</td>
<td>NA</td>
<td>Prior cEBRT dose &gt;35 Gy, trend for time interval to re-treat &gt;12 mos (p = 0.05) on univariate analysis</td>
</tr>
<tr>
<td>Damast et al., 2011</td>
<td>97/95</td>
<td>12.1</td>
<td>66% @ 1 yr</td>
<td>46%</td>
<td>52–59% @ 1yr</td>
<td>20 Gy/5 Fx or 30 Gy/5 Fx (median dose 30 Gy/NA Fx)</td>
<td>30 Gy/5 Fx associated w/ better local control vs 20 Gy/5 Fx</td>
<td>KPS, radiosensitve histology; time interval to re-treat &gt;12 mos</td>
</tr>
<tr>
<td>Chang et al., 2012</td>
<td>54/49</td>
<td>17.3</td>
<td>81% @ 1 yr</td>
<td>81% (1 yr)</td>
<td>Median OS: 11 mos</td>
<td>20.6 Gy/1 Fx (mean cEBRT EQD2 39.2Gy)</td>
<td>Presence of epidural disease</td>
<td>NA</td>
</tr>
<tr>
<td>Thibault et al., 2015</td>
<td>5640 (24/56 cEBRT followed by 2 courses SBRT; 32/56 SBRT &amp; a 2nd course SBRT)</td>
<td>6.8</td>
<td>81.6% @ 1 yr/71.5% @ 2 yrs</td>
<td>NA</td>
<td>48% @ 1 yr</td>
<td>Median 30 Gy/4 Fx (24/56, median cEBRT = 22.5 Gy/5 Fx &amp; 1st course SBRT = 24 Gy/2 Fx; 32/56 median 1st course SBRT = 24 Gy/2 Fx)</td>
<td>Presence of paraspinal soft tissue disease</td>
<td>Time interval btw 1st SBRT &amp; 2nd SBRT</td>
</tr>
</tbody>
</table>

GTV = gross tumor volume; NA = not available; OS = overall survival; pts = patients.
comparative purposes has been debated in the recent literature.\(^3,3\) Lastly, some argue that for low α/β tumors the biological effectiveness for single-fraction SBRT is likely greater than for multiple-fraction SBRT, and this effect diminishes as the α/β increases. At this time, we do not have the ability to determine a priori the tumor α/β, and it may be a biological confounding factor when trying to describe the effects of dose on tumor control. Those supporting multiple-fraction SBRT argue that re-oxygenation and redistribution yield a radiobiological advantage to enhance local tumor control, the threshold for tumor endothelial cell apoptosis activation is not conclusively known, delivery of repetitive SBRT fractions may overcome tumor hypoxia and induce more dramatic cumulative ischemic injury, and fractionated SBRT may induce a greater immunological response as compared with single-fraction SBRT.\(^1\) Ultimately, a randomized comparative trial evaluating single-fraction SBRT versus multiple-fraction SBRT will be required; moreover, the trial should evaluate effects specific to both histological type and molecular profile.

The major weakness of this study is its retrospective design. We did observe that 74.3% of patients had reported improvement in their pain, and, at last follow-up, pain was present in only 46.1% of patients. These data were based on chart review and not a formalized pain assessment tool with prospective documentation of the numerical pain score. Furthermore, medication details could not be reliably recorded to determine whether the subjectively documented pain response was confounded by the use of analgesics. Ideally, international consensus response end points for pain control are the standard,\(^7\) but they can only be achieved in a clinical trial. Nevertheless, our results are not unreasonable given prior pain response outcomes as shown in Table 3, and similar to previous studies, our study showed low rates of adverse events. Spine SBRT was well tolerated with respect to acute toxicity in this series. However, these events are typically poorly documented, and a prospective study design and rigorous data acquisition are required for accurate outcomes. Documentation of late effects is more reliable despite the retrospective nature of the study given the permanent nature of the event and urgency of determining a cause upon clinical deterioration. Most importantly, we observed no cases of radiation-induced myelopathy, and this may reflect practice that was consistent with prior published spinal cord dose limits specific to re-irradiation SBRT.\(^26\) Five percent of our patients did suffer from a VCF. This crude rate is lower than expected, based on our literature review, which shows re-irradiation VCF rates ranging from 10% to 16% (Table 3). Notably, Thibault et al. reported no VCF in 19 patients without any prior surgery and treated with multiple-fraction salvage SBRT (most commonly 30 Gy in 4 fractions).\(^28\) This is a high-risk group, given that the patients had prior SBRT (many also had prior cEBRT and SBRT) and then were treated with a second course of SBRT to the same level; hence, the cumulative doses to the tumors are much greater than in patients who had previously been treated with cEBRT alone (without SBRT) and were then treated with SBRT. The authors’ result may reflect the effect of patient selection. We hypothesize that the low rates of VCF in this population may also be explained by patient selection. For example, 46% of patients had a surgical procedure prior to SBRT, implying that our cohort consisted mainly of patients at low risk of VCF, as those at high risk of VCF were likely to have undergone a surgical stabilization procedure at some point prior to re-irradiation SBRT. Overall, the low rate of VCF does suggest that this practice is safe with respect to tolerance of the bone, and it highlights the need to understand a priori radiation tolerance of the vertebral body bone for proper patient selection.

This multi-institutional cohort study provides valuable data on efficacy and safety of re-irradiation spine SBRT for patients with spinal metastases after failure of initial cEBRT. We observed high rates of local control and pain control consistent with those reported for smaller single-institution series. Patients with a poor performance status (KPS < 70) may not survive long enough to benefit from this resource-intensive therapy. At present, single-fraction SBRT may provide superior rates of efficacy as compared with multiple-fraction SBRT; however, we cannot be definitive, as the quality of the evidence in general is low and dose-finding randomized trials are needed.

References

Disclosures
This research was supported by Elekta AB as a research grant to the principal investigator Dr. Matthias Guckenberger. Each author belongs to the Elekta Spine Study Consortium, which is supported by Elekta AB. Dr. Arjun Sahgal has received honoraria for past educational seminars from Medtronic and Elekta AB and research grants from Elekta AB. The data collection, interpretation, writing and final approval was independent of industry participation. Dr. Grills also reports an ownership interest in Greater Michigan Gamma Knife.

Author Contributions
Conception and design: all authors. Acquisition of data: all authors. Analysis and interpretation of data: Hashmi, Guckenberger, Sahgal. Drafting the article: all authors. Critically revising the article: all authors. Reviewed submitted version of manuscript: all authors. Approved the final version of the manuscript on behalf of all authors: Sahgal. Statistical analysis: Hashmi, Guckenberger, Sahgal. Administrative/technical/material support: Guckenberger, Sahgal. Study supervision: Guckenberger, Sahgal.

Correspondence
Arjun Sahgal, Department of Radiation Oncology, University of Toronto, Sunnybrook Health Sciences Centre, 2075 Bayview Ave., Toronto, ON M4N 3M5, Canada. email: arjun.sahgal@sunnybrook.ca.